(Q38444112)

English

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients

scientific article published on July 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients (English)

1 reference

Europe PubMed Central

3 September 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kulisevsky J

1

1 reference

Europe PubMed Central

3 September 2017

García-Sánchez C

2

1 reference

Europe PubMed Central

3 September 2017

Berthier ML

3

1 reference

Europe PubMed Central

3 September 2017

Barbanoj M

4

1 reference

Europe PubMed Central

3 September 2017

Pascual-Sedano B

5

1 reference

Europe PubMed Central

3 September 2017

Gironell A

6

1 reference

Europe PubMed Central

3 September 2017

Estévez-González A

7

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

1 July 2000

1 reference

Europe PubMed Central

3 September 2017

Movement Disorders

1 reference

Europe PubMed Central

3 September 2017

15

1 reference

Europe PubMed Central

3 September 2017

4

1 reference

Europe PubMed Central

3 September 2017

613-626

1 reference

Europe PubMed Central

3 September 2017

Cognitive function in Parkinson's disease: From description to theory

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Memory disturbance and the Parkinson syndrome

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

High speed memory scanning in parkinsonism

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Cognitive concomitants of dopamine system stimulation in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Levodopa and psychometric test performance in parkinsonism-5 years later

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

When did Ray Kennedy's Parkinson's disease begin?

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

The role of dopamine agonists in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Issues associated with repeated neuropsychological assessments

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Demonstration of savings on the AVLT and development of a parallel form

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Studies of interference in serial verbal reactions

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunction.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Parkinson's disease. Cognitive changes in relation to treatment response

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Cognitive impairments associated with early Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Levodopa's awakening effect on patients with Parkinsonism

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Dissociation of object and spatial processing domains in primate prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

A central executive deficit in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Fronto-striatal cognitive deficits at different stages of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Reward expectancy in primate prefrontal neurons.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Regional and cellular fractionation of working memory

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Is the mesocortical dopaminergic system involved in Parkinson disease?

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Dopamine autoreceptor function is lost in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Interaction of pergolide with central dopaminergic receptors

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

A Standardized Memory Scale for Clinical Use

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C613%3A%3AAID-MDS1005%3E3.0.CO%3B2-F

21 January 2018

Identifiers

10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38444112&oldid=1760116244"